Plasma membrane pannexin 1 channels (PANX1) release nucleotide find-me signals from apoptotic cells to attract phagocytes. Here we show that the quinolone antibiotic trovafloxacin is a novel PANX1 inhibitor, by using a small-molecule screen. Although quinolones are widely used to treat bacterial infections, some quinolones have unexplained side effects, including deaths among children. PANX1 is a direct target of trovafloxacin at drug concentrations seen in human plasma, and its inhibition led to dysregulated fragmentation of apoptotic cells. Genetic loss of PANX1 phenocopied trovafloxacin effects, revealing a non-redundant role for pannexin channels in regulating cellular disassembly during apoptosis. Increase in drug-resistant bacteria worldwide and the dearth of new antibiotics is a major human health challenge. Comparing different quinolone antibiotics suggests that certain structural features may contribute to PANX1 blockade. These data identify a novel linkage between an antibiotic, pannexin channels and cellular integrity, and suggest that re-engineering certain quinolones might help develop newer antibacterials.
Plasma membrane pannexin 1 channels (PANX1) release nucleotide find-me signals from apoptotic cells to attract phagocytes. Here we show that the quinolone antibiotic trovafloxacin is a novel PANX1 inhibitor, by using a small-molecule screen. Although quinolones are widely used to treat bacterial infections, some quinolones have unexplained side effects, including deaths among children. PANX1 is a direct target of trovafloxacin at drug concentrations seen in human plasma, and its inhibition led to dysregulated fragmentation of apoptotic cells. Genetic loss of PANX1 phenocopied trovafloxacin effects, revealing a non-redundant role for pannexin channels in regulating cellular disassembly during apoptosis. Increase in drug-resistant bacteria worldwide and the dearth of new antibiotics is a major human health challenge. Comparing different quinolone antibiotics suggests that certain structural features may contribute to PANX1 blockade. These data identify a novel linkage between an antibiotic, pannexin channels and cellular integrity, and suggest that re-engineering certain quinolones might help develop newer antibacterials.
Pannexins are four-pass transmembrane channels identified as a new family of channels for small molecules (up to ,1 kDa) across the plasma membrane 1, 2 . Among the three vertebrate pannexin family members (PANX1, PANX2 and PANX3), PANX1 is the most widely expressed 1 and is implicated in regulating neutrophil activation 3 , airway inflammation 4 , human immunodeficiency virus infection 5 , vasoconstriction 6 , migraine 7 and other neurological disorders 8, 9 . This broad and diverse range of functions may in part arise from pannexin channel-mediated release of purines such as ATP into the extracellular space, where purinergic signalling can influence multiple physiological processes 10, 11 . Thus, PANX1 is an attractive therapeutic target for human diseases and we sought to identify small molecules that can modulate PANX1 function.
Trovafloxacin inhibits PANX1 channel activity
Caspase-mediated cleavage of PANX1 carboxy terminus during apoptosis leads to PANX1 channel opening and release of nucleotide findme signals from early apoptotic cells to recruit phagocytes [12] [13] [14] [15] (Fig. 1a ). This channel opening also allows the entry of fluorescent dyes, including TO-PRO-3 13, 15 (Fig. 1a ). We optimized TO-PRO3 uptake by apoptotic Jurkat cells as a reliable, medium-throughput, flow-cytometry-based assay for monitoring PANX1 activity. We tested a 'library of pharmacologically active compounds' (LOPAC 1280 ) containing 1,280 small molecules targeting a diverse range of cellular processes-including currently marketed drugs, failed candidates, and bioactive molecules with known activities. The initial screen revealed three potential PANX1 inhibitors that were tested in secondary screens. Among them, trovafloxacin (a quinolone-based antibiotic) was identified as a potent inhibitor of TO-PRO-3 uptake by apoptotic cells (Fig. 1b ). The use of trovafloxacin in patients has been linked to serious adverse side effects, including effects on the central nervous system, hepatic toxicity and in some cases mortality, but the molecular target(s) of trovafloxacin in mammalian cells is unclear 16, 17 . Trovafloxacin inhibition of PANX1 was dose-dependent, and comparable to the known pannexin inhibitor carbenoxolone (CBX) ( Fig. 1c ). Trovafloxacin also inhibited ATP release from apoptotic cells ( Fig. 1d ). Importantly, trovafloxacin did not inhibit caspase 3/7 activation, or caspase-mediated PANX1 cleavage during apoptosis (Extended Data Fig. 1a, b ), ruling these out as reasons.
Several additional analyses suggested trovafloxacin could directly target PANX1 channel activity. Adding trovafloxacin to cells already undergoing apoptosis (that is, with open PANX1 channels) acutely blocked TO-PRO-3 uptake (Extended Data Fig. 1c, d ). When we measured apoptosis-induced plasma membrane PANX1 currents at the single-cell level, by whole-cell patch-clamp recordings, trovafloxacin rapidly inhibited the inward current (at 250 mV), with minimal effect on outward current (at 180 mV) ( Fig. 1e and Extended Data Fig. 1e ). We have previously shown that the C-terminal tail of PANX1 blocks the channel pore, and that adding excess soluble C-terminal tails can inhibit 'open' PANX1 channels, especially the inward current (analogous to trovafloxacin) 14 . In contrast, CBX blocked both inward and outward currents 13, 18, 19 (Fig. 1e , f). Trovafloxacin did not inhibit connexin 43 gap junction or PANX2 (Extended Data Fig. 1f -i). Using a tobacco etch virus (TEV)-protease system to cleave the C-terminal tail of recombinant PANX1 and induce channel activity (independent of apoptosis) 13, 14 , trovafloxacin again potently blocked open PANX1 channels ( Fig. 1g ). To test direct channel blocking, we recorded TEV-cleaved PANX1 single-channel activity in excised inside-out patch-clamp by adding trovafloxacin to the patch; this led to an increase in the time spent in the closed state, with open probability (NPo) of ,0.85 in control conditions reduced to ,0.15 with trovafloxacin ( Fig. 1h ). The half maximal inhibitory concentration (IC 50 ) of trovafloxacin was ,4 mM for the PANX1 inward current ( Fig. 1i ), similar to concentrations normally achieved in human plasma (2-10 mM) 20, 21 . These data indicated that mammalian PANX1 channels could be a direct target of antibiotic trovafloxacin.
Trovafloxacin promotes fragmentation of apoptotic cells
Next, we investigated trovafloxacin effects on apoptotic cells via microscopy and made several surprising observations. Apart from reducing TO-PRO-3 uptake by apoptotic cells, trovafloxacin also induced the formation of smaller particles; these 'fragments of apoptotic cells' were annexin V 1 , indicating phosphatidylserine exposure, and resembled apoptotic bodies that arise after cell disassembly during apoptosis 22, 23 ( Fig. 2a, b ). To quantify these apoptotic bodies, we designed a flowcytometry-based assay (Extended Data Fig. 2a , b) to analyse five parameters simultaneously: cell size (forward scatter, FSC), cellular complexity (side scatter, SSC), annexin V staining (indicating apoptosis), TO-PRO-3 uptake (PANX1 opening), and 7-aminoactinomycin D (7-AAD) staining (loss of plasma membrane integrity). We also performed Image-Stream analysis, which combines flow cytometry and image acquisition to confirm the categorization of cells and apoptotic bodies (Extended Data Fig. 2c ). The apoptotic bodies were annexin V intermediate (compared to annexin V high apoptotic cells), with smaller size and reduced complexity (Extended Data Fig. 2 ). Trovafloxacin promoted the formation of apoptotic bodies in a concentration-dependent manner ( Fig. 2c, d) . Importantly, without an apoptotic stimulus, trovafloxacin did not induce apoptosis or apoptotic bodies (Extended Data Fig. 1a ), indicating that trovafloxacin probably modulates steps during apoptosis that promote cellular disassembly. Although trovafloxacin itself did not induce apoptosis, because the human body turns over more than 200 billion cells daily via apoptosis as part of homeostasis 24 , trovafloxacin could affect these apoptotic steps.
PANX1 regulates the disassembly of apoptotic cells
Although some studies have addressed apoptotic cell disassembly, the mechanisms that control the formation of apoptotic bodies are not well understood 22, 23, 25, 26 . Several lines of evidence suggested a key role for PANX1 in regulating apoptotic cell integrity/disassembly. First, blocking pannexin channels in apoptotic Jurkat cells with CBX or probenecid (another pannexin inhibitor 27 ) promoted formation of apoptotic bodies ( Fig. 2e, f) . Second, this effect was not dependent on the mode of apoptosis induction, as blocking PANX1 during Fas-or ultravioletmediated apoptosis promoted formation of apoptotic bodies ( Fig. 2f and Extended Data Fig. 3a ). Third, using loss of cellular complexity during apoptosis as an indication of fragmentation of larger apoptotic cells (SSC high /higher cellular complexity) into smaller apoptotic bodies (SSC low /lower cellular complexity), blocking PANX1 reduced the number of SSC high particles ( Fig. 2g ). Treating wild-type primary thymocytes undergoing apoptosis ex vivo with trovafloxacin, CBX or probenecid also led to more apoptotic bodies with reduced cellular complexity ( Fig. 3a, b ). Fourth, the enhanced apoptotic bodies correlated inversely with TO-PRO-3 uptake (Extended Data Fig. 3b ), with progressively more PANX1 channel blocking leading to greater formation of apoptotic bodies. Fifth, in a genetic approach, overexpressing a dominant negative form of PANX1 (PANX1 DN) with a mutant caspase cleavage site that can interfere with endogenous PANX1 function 13 (Extended Data Fig. 4a ) resulted in increased formation of apoptotic bodies (Fig. 2h ). Conversely, overexpressing wild-type PANX1 led to fewer apoptotic bodies. This 'gain of function' due to wild-type PANX1 expression was still dependent on PANX1 channel activity, with reversal by PANX1 blockers (Fig. 2i ). Lastly, blocking PANX1 channel functions did not affect some known apoptotic features such as DNA fragmentation (Extended Data Fig. 4b ) or phosphatidylserine exposure ( Fig. 2b ). Collectively, these data identify PANX1 as a regulator of cellular disassembly during apoptosis.
Trovafloxacin and PANX1 regulate apoptotic cell disassembly in vivo
To address how trovafloxacin and PANX1 might affect apoptosis in a whole animal, we used intraperitoneal dexamethasone injection to induce synchronous apoptosis of a large fraction of mouse thymocytes in vivo 12,28 (Fig. 3c ). Administering trovafloxacin with dexamethasone promoted the fragmentation of the apoptotic thymocytes ( Fig. 3d , with fewer SSC high particles; see Extended Data Figs 5 and 6 for gating strategy). However, in these experiments we could not track thymic trovafloxacin concentrations, and trovafloxacin in vivo could also have had other effects beyond PANX1. Therefore, we generated mice carrying deletion 
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of Panx1, using embryonic stem cells engineered to disrupt the Panx1 gene (Extended Data Fig. 7 ). In the thymus of Panx1 2/2 and Panx1 1/2 mice treated with dexamethasone, the fragmentation of apoptotic cells was enhanced ( Fig. 3e ), essentially phenocopying the effect of trovafloxacin treatment in wild-type mice (Fig. 3d ). The apoptotic particles from Panx1 2/2 and Panx1 1/2 mice also showed reduced TO-PRO-3 uptake ( Fig. 3e ). To rule out that loss of PANX1 in other tissues contributed to the observed thymic phenotypes in the global knockout mice, we specifically deleted Panx1 in thymocytes by crossing the Panx1 fl/fl mice with Lck-Cre mice, where Cre is expressed in the T-cell lineage (Extended Data Fig. 7 ). Similar apoptotic fragmentation and loss of TO-PRO-3 uptake were observed when PANX1 was deleted specifically in thymocytes ( Fig. 3f ), indicating a cell-autonomous effect. Ex vivo, apoptotic thymocytes from PANX1 global knockout mice or the Lck-Cre/Panx1 fl/fl mice also showed enhanced formation of apoptotic bodies, decreased TO-PRO-3 uptake and reduced cellular complexity ( Fig. 3g -i). Collectively, these data indicate that PANX1 critically influences cellular integrity of dying cells, with loss of PANX1 function either genetically or via trovafloxacin treatment promoting disassembly of apoptotic cells. One possible mechanism for this increased cellular fragmentation is the lack of ATP that would normally be released by apoptotic cells, and the various autocrine and paracrine signalling via P2 purinergic receptors 3, 5, 12, 13, 29 . However, adding exogenous ATP to apoptotic cells when PANX1 channel activity was blocked did not inhibit apoptotic bodies formation (Extended Data Fig. 3c, d) . Conversely, adding recombinant apyrase (to hydrolyse ATP) during induction of apoptosis did not promote the formation of apoptotic bodies (Extended Data Fig. 3e ). Furthermore, treatment with suramin, a broad inhibitor of P2 family G-protein-coupled receptors, did not enhance formation of apoptotic bodies (Extended Data Fig. 3f ). Thus, the extracellular ATP levels and P2 purinergic receptor signalling are probably not directly involved in regulating apoptotic cell integrity.
PANX1 regulates formation of string-like apoptopodia
We next used time-lapse microscopy to monitor cell morphology and TO-PRO-3 uptake. In our experimental conditions with Jurkat cells induced to undergo Fas-mediated apoptosis, most cells begin to show rounding and membrane blebs around 60-90 min, and continue to bleb for another 30-60 min, a time period referred here as 'dynamic blebbing'. Remarkably, very few of these blebs detach from the apoptotic cell, and after cessation of the dynamic blebbing, these blebs remain attached to the dying cell (Fig. 4a, b and Supplementary Video 1). When we added TO-PRO-3 into the medium and tracked its uptake as a measure of PANX1 activity, TO-PRO-3 staining was detected before cell rounding and the onset of blebbing ( Fig. 4c and Extended Data Fig. 4c ). This indicates that PANX1 channels are activated/opened before detection of membrane blebbing. When we compared cells with normal or impaired PANX1 function (treated with trovafloxacin or CBX, or expressing PANX1 DN mutant), a previously unappreciated step during dynamic membrane blebbing regulated by pannexin channels was revealed. Specifically, apoptotic cells with impaired PANX1 function produced long string-like structures, which we preliminarily denote 'apoptopodia', with blebs of different sizes attached to the ends (Fig. 4a,  b, d and Supplementary Videos 2 and 3) . These apoptopodia were annexin V 1 , indicating phosphatidylserine exposure (Fig. 4e ). Whereas few apoptopodia were seen in apoptotic cells with normal PANX1 function, their frequency was substantially increased by blocking PANX1 (Fig. 4f ). Blocking PANX1 function in live cells (either pharmacologically or using the PANX1 DN mutant) did not cause apoptopodia (data not 
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shown), indicating that pannexin channels regulate the formation of these membrane protrusions after apoptosis induction. These apoptopodia were also observed in apoptotic thymocytes from PANX1 knockout mice, or wild-type thymocytes treated with pannexin inhibitors (Fig. 3j ). Fas-, dexamethasone-or ultraviolet-induced apoptosis led to apoptopodia formation when PANX1 function was impaired (data not shown).
We next asked how the apoptopodia formation and membrane blebbing were linked. PANX1-mediated TO-PRO-3 uptake began before the onset of blebbing (Fig. 4c ), but the apoptopodia were detectable only after the onset of blebbing (Fig. 4b, g ). This indicates that PANX1 activity is probably continuously required during apoptosis progression to downregulate the formation of apoptopodia. Interestingly, when blebbing was blocked by inhibiting actomyosin contraction or the Rhodependent kinase ROCK (which are needed for apoptotic blebbing 22, 30, 31 ), apoptopodia formation was unaffected, with noticeable absence of blebs at the end of these strings (Extended Data Fig. 8a-c) . Importantly, inhibiting blebbing reduced the formation of apoptotic bodies in Jurkat cells with PANX1 function disrupted by pharmacological block, or in PANX1-deficient thymocytes (Extended Data Fig. 8d-f ). These data indicate that the apoptopodia that arise owing to PANX1 inhibition are independent of blebbing, but that the annexin V 1 vesicular structures seen at the end of apoptopodia are dependent on blebbing and contribute to apoptotic bodies formation. LR73 fibroblasts induced to undergo apoptosis also showed the formation of apoptopodia and apoptotic bodies when PANX1 function was impaired (Extended Data Fig. 9 ). Thus, trovafloxacin-mediated enhancement of apoptotic bodies formation helped uncover a new step during the early stages of apoptosis; specifically, pannexin channel function is required to restrain detachment of blebs from the apoptotic cells, and in turn, regulate the nature of apoptotic cell disassembly (Extended Data Fig. 10 ).
PANX1 inhibition varies among different quinolones
Although quinolone antibiotics are effective at killing bacteria by targeting their topoisomerases, and are used worldwide to treat various bacteria infections [32] [33] [34] , some quinolones have serious side effects (incidence up to 5%) in the liver, skin, tendon, gastrointestinal tract, central nervous system and cardiovascular system that are not readily explained 16, 17 . 
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Surprisingly, in contrast to trovafloxacin, two other structurally related quinolone antibiotics ciprofloxacin and levofloxacin did not block PANX1dependent dye uptake (Fig. 1c) , despite all three being equally effective in inhibiting bacterial growth (Extended Data Fig. 1j ). Comparing the molecular structure of trovafloxacin with ciprofloxacin and levofloxacin suggested that certain features of trovafloxacin, such as the fluorinated ring at position N1 (Fig. 4h) , might contribute to its effect on PANX1 (Figs 1c and 2d) . We next asked whether other quinolones with a fluorinated ring at position N1 can inhibit PANX1, and tested difloxacin and tosufloxacin (Fig. 4h ) that are currently available commercially in some Asian countries. Although less potent than trovafloxacin, both difloxacin and tosufloxacin partially inhibited ATP release and TO-PRO-3 uptake by apoptotic cells, and promoted the formation of apoptotic bodies (Fig. 4i) . These data do not exclude other molecular features of trovafloxacin that may also contribute to PANX1 inhibition, such as the C7 position of the quinolone (Fig. 4h ).
Discussion
The data presented here suggest an unexpected but intriguing link between the antibiotic trovafloxacin, eukaryotic pannexin channels, 
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and a specific step in progression through apoptosis. Specifically, they provide three key insights. First, trovafloxacin, originally marketed by Pfizer, showed tremendous promise, but was linked to severe toxicity and unexplained deaths among children in a trial in Nigeria, and was discontinued 16, 35 . Because billions of cells are turned over daily via caspasemediated apoptosis in the human body as part of normal life, and trovafloxacin can directly inhibit the mammalian PANX1 channels at doses normally achieved in humans, this could, in part, provide a mechanism for trovafloxacin toxicity. Second, our data identify a new role for pannexin channels in maintaining cellular integrity during apoptosis. Fragmentation of apoptotic cells into smaller apoptotic bodies has been seen in vitro and in vivo 22 , but the mechanism(s) regulating this disassembly process is not well understood. The trovafloxacin-mediated blockage of PANX1 uncovered a previously unappreciated step during apoptosis, and revealed an essential and non-redundant role for pannexin channels in the ordered disassembly of apoptotic cells. Third, the dearth of new antibiotics in the pipeline despite the steady increase in drug-resistant bacteria worldwide 33, 34 is a significant health threat 36 . Interestingly, quinolone antibiotics such as ciprofloxacin and levofloxacin do not share the inhibitory effect of trovafloxacin towards the mammalian PANX1, and certain features in trovafloxacin might in part explain its toxicity. Further studies on the interaction of quinolones with PANX1 and the associated apoptosis pathways may provide clues to the underlying reasons for the idiosyncratic and irreversible liver toxicity observed with trovafloxacin. Unlocking such clues could re-invigorate industrial interest in the quinolone class for the production of safer, and more potent antibacterials.
METHODS SUMMARY
For drug screening targeting pannexin channels, Jurkat cells were induced to undergo apoptosis (4 h) by anti-Fas (250 ng ml 21 ) in the presence of 10 mM of each compound from the LOPAC 1280 library (Sigma-Aldrich). Cells were then stained with TO-PRO-3 and analysed by flow cytometry. Chimeric mice were generated using Panx1-targeted embryonic stem cells (from KOMP repository) and crossed to bactin/Flp mice (JaxMice) to delete the neomycin cassette, and crossed with Ella-Cre mice (JaxMice) or Lck-Cre mice (JaxMice) to delete PANX1 globally or specifically in thymocytes, respectively. For determining apoptotic cell fragmentation by flow cytometry, Jurkat cells were stained with annexin V-FITC, 7-AAD and TO-PRO-3, whereas thymocytes from in vivo experiments were stained similarly with annexin V-FITC, 7-AAD, TO-PRO-3, CD8a conjugated with phycoerythrin and CD4 conjugated with phycoerythrin-Cy7, with gating as per Extended Data Figs 2, 5 and 6. For time-lapse microscopy, cells seeded onto Lab-TekII Chambered Coverglass (Nunc) were imaged live using a Zeiss microscope in a 37 uC/5% CO 2 atmosphere. Whole-cell and inside-out patch recordings were made as described 13, 14 (see Methods). A ramp voltage was performed using pCLAMP software and a Digidata 1322A digitizer (Molecular Devices), with data analysed by pCLAMP software.
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